Reduction of dermal scarring

Details Reduction of dermal scarring Reduction of dermal scarring

2004-11-23

2008-12-16

Wilson, Michael C. (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C514S514000, C424S093210

Reexamination Certificate

active

07465442

ABSTRACT:
Methods and compositions for reducing or inhibiting dermal scarring by expressing p21WAF1/Cip1in a wound site are provided.

REFERENCES:
patent: 5302706 (1994-04-01), Smith et al.
patent: 5424400 (1995-06-01), Smith et al.
patent: 5596079 (1997-01-01), Smith et al.
patent: 5621082 (1997-04-01), Xiong et al.
patent: 5624819 (1997-04-01), Skolnick et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5827702 (1998-10-01), Cuthbertson
patent: 5837520 (1998-11-01), Shabram et al.
patent: 5840845 (1998-11-01), Smith et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5994934 (1999-11-01), Yoshimura et al.
patent: 6027742 (2000-02-01), Lee et al.
patent: 6204251 (2001-03-01), Cuthbertson
patent: 6210939 (2001-04-01), Gregory
patent: 6218372 (2001-04-01), Nabel et al.
patent: 6242201 (2001-06-01), Lane et al.
patent: 6274614 (2001-08-01), Richter et al.
patent: 6372249 (2002-04-01), Smith et al.
patent: 6489305 (2002-12-01), Demers
patent: 6818215 (2004-11-01), Smith
patent: 2002/0111304 (2002-08-01), Kazlauskas et al.
patent: B-61444/94 (1994-09-01), None
patent: 0640143 (2001-03-01), None
patent: 0783317 B13 (2004-11-01), None
patent: WO 93/012251 (1993-06-01), None
patent: WO 94/09135 (1994-04-01), None
patent: WO 95/006415 (1995-03-01), None
patent: WO 95/28483 (1995-10-01), None
patent: WO 95/031995 (1995-11-01), None
patent: WO 96/012506 (1996-05-01), None
patent: WO 96/14334 (1996-05-01), None
patent: WO 96/19244 (1996-06-01), None
patent: WO 96/35704 (1996-11-01), None
patent: WO 97/03635 (1997-02-01), None
patent: WO 97/11174 (1997-03-01), None
patent: WO 97/37542 (1997-10-01), None
Verma et al. (1997) Nature, vol. 389, p. 239.
Pfeifer and Verma (2001) Annu. Rev. Genomics. Hum. Genet. 2:177-211.
Johnson-Saliba et al. (2001) Curr. Drug. Targets 2:371-99.
Shoji et al. (2004) Current Pharmaceutical Design 10 :785-796.
Perkins et al.(Jul. 2002) Arch. Ophthalmol. 120:941:949.
Siemens et al. (2000) J. Nat. Can. Inst. 92:403-412.
Scherer et al. (Sep., 2002) J. of Gene Med. 4:634-643.
Online Medical Dictionary Definition of “skin”.
Online Medical Dictionary Definition of “cornea”.
Liu (Annals of plastic surgery, May 2000, vol. 44, No. 5, pp. 543-551, abstract only).
Church, Invest. Ophtalmology & Visual Sci., 1981, vol. 21, No. 1, pp. 73-79.
Kim, Invest. Ophtalmology & Visual Sci. 1990, vol. 31, No. 6, pp. 1183-1186.
U.S. Appl. No. 90/007,466, Demers.
Afshari, Cynthia A. et al.; “A Role for a p21-E2F Interaction during Senescence Arrest of Normal Human Fibroblasts”; 1996,Cell Growth&Difference, vol. 7, pp. 979-988.
Al-Aswad, L.A. et al.; “Inhibition of fibroblast proliferation and enhancement of glaucoma filtration surgery in the rabbit with cytosine arabinoside”; 1996,Investigative Ophthalmology, vol. 37, vol. 3, p. S23, abstract.
Alcorta, David A. et al.; “Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.”; 1996,Proc. Natl. Acad. Sci., vol. 93, pp. 13742-13747.
Ali, Robin R. et al.; “Gene transfer into the mouse retina mediated by an adeno-associated viral vector”; 1996,Hum. Mol. Genet., vol. 5, pp. 591-594.
Arteaga, Carlos L. et al; “Tissue-targeted Antisense c-fosRetroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice”; 1996,Cancer Research, vol. 56, No. 5, pp. 1098-1103.
Atreides, Sean-Paul A. et al.; “Wound Healing Modulation in Glaucoma Filtering Surgery”; 2004,International Ophthalmology Clinics, vol. 44, No. 2, pp. 61-106.
Bennett, Jean et al; “Humoral Response after Administration of E1-Deleted Adenoviruses: Immune Privilege of the Subretinal Space”; 1996,Hum. Gene Ther., vol. 7, pp. 1763-1769.
Bridge, Eileen et al.; “Redundant Control of Adenovirus Late Gene Expression by Early Region 4”; 1989, Journal of Virology, vol. 63, No. 2, pp. 631-638.
Cayrol, Corinne, et al.,; “p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53- deficient cells”; 1998,Oncogene, vol. 16, pp. 311-320.
Cayouette, Michel et al.; “Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse”; 1997,Hum. Gen Ther., vol. 8, pp. 423-430.
Chang, Mark W. et al.; “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty”, 1995,J. Clin. Invest., vol. 96, pp. 2260-2268.
Dalesandro, Joy et al; “Cardiac and Pulmonary Replacement”; 1996,J. Thorac. Cardi. Surg. vol. 111, No. 2, pp. 416-422.
da Cruz L., et al., ; “Ocular gene therapy: The basic science and current state of research”; 1997,Aust N.Z. J. Opthalmol., vol. 25, pp. 97-104.
Della Neil G.; “Molecular Biology in Ophthalmology. A Review of Principles and Recent Advances.”, 1996,Arch. Ophthalmol., vol. 114, pp. 457-463.
Denhardt, David T.; “Oncogene-Initiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Theraphy.”; 1996,Crit. Rev. Oncog., vol. 7, pp. 261-291.
Divan A., et al., ; “p53 expression correlates with apoptosis but not with p21, waf expression in retinoblastomas”; 1997,Journal of Pathology, vol. 182, pp. 6A.
Dunaief, Joshua L. et al.; “Retroviral Gene Transfer into Retinal Pigment Epithelial Cells Followed by Transplantation into Rat Retina”; 1995,Hum. Gene Ther., vol. 6, pp. 1225-1229.
Eastham James A., et al.; “In vivo gene therapy withp53orp21Adenovirus for Prostate Cancer.”; 1995,Cancer Res., vol. 55, pp. 5151-5155.
Erhardt, Joseph A. et al.; “p21WAF1induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells.”; 1998,Oncogene, vol. 16, pp. 443-451.
Fromm, Larry et al.; “Inhibition of Cell Death by Lens-Specific Overexpression of bcl-2 in Transgenic Mice”; 1997,Dev. Genet., vol. 20, pp. 276-287.
Gartel A.L., et al.; “p21—Negative Regulator of the Cell Cycle.”; 1996,Proc. Soc. Exp. Biol. Med., vol. 213, pp. 138-149.
Hermens, Wim T.J.M.C. et al.,; “Transient gene transfer to neurons and glia: Analysis of adenoviral vector performance in the CNS and PNS”; 1997,J. Neurosci. Methods, vol. 71, pp. 85-98.
Jomary, C. et al.; “Adenovirus-mediated gene transfer to murine retinal cells in vitro and in vivo”; 1994,FEBS letters, vol. 347, pp. 117-122.
Khaw, Peng T. et al.; “Effects of Intraoperative 5-Fluorouracil or Mitomycin C on Glaucoma Filtration Surgery in theRabbit”; 1993,Ophthalmology, vol. 100, pp. 367-372.
Koc, Omer N. et al.; “Transfer of Drug Resistance Genes Into Hematopoietic Progenitors to Improve Chemotherapy Tolerance”; 1996,Seminars in Oncology, vol. 23, No. 1, pp. 46-65.
Ledley, Fred D.; “Pharmaceutical Approach to Somatic Gene Therapy”; 1996,Pharmaceutical Research, pp. 1595-1614.
Lee, David A. et al.; “The Effects of the Fluorinated Pyrimidines FUR, FUdr, FUMP, and FdUMP, on Human Tenon's Fibroblast”; 1991,Investigation Ophthalmology&Visual Science, vol. 32, No. 9, pp. 2599-2609.
Li, Tiansen et al.; “Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer”; 1995,Proc. Natl. Acad. Sci. U.S.A.vol. 92, pp. 7700-7704.
Makarov, Sergei S. et al.; “Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA”; 1996,Proc. Natl. Acad. Sci. U.S.A.vol. 93, pp. 402-406.
Mashhour, Babak et al.; “In vivo adenovirus-mediated gene transfer into ocular tissues”; 1994,Gene Ther. vol. 1, No. 2, pp. 122-126.
Medema, René H. et al., “p21waf1can block cells at two points in the cell cycle, but does not inter

Affiliated with

Also associated with

Rating

Reduction of dermal scarring does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of dermal scarring, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of dermal scarring will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4038495